UK markets closed

Galmed Pharmaceuticals Ltd. (GLMD)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3775-0.0096 (-2.48%)
As of 10:33AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.33M
Enterprise value -10.27M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.17
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.38

Trading information

Stock price history

Beta (5Y monthly) 0.87
52-week change 329.00%
S&P500 52-week change 323.57%
52-week high 35.6300
52-week low 30.2600
50-day moving average 30.3621
200-day moving average 30.5138

Share statistics

Avg vol (3-month) 3212.54k
Avg vol (10-day) 344.77k
Shares outstanding 56.01M
Implied shares outstanding 66.01M
Float 85.78M
% held by insiders 13.87%
% held by institutions 19.44%
Shares short (15 Apr 2024) 479.03k
Short ratio (15 Apr 2024) 40.18
Short % of float (15 Apr 2024) 41.37%
Short % of shares outstanding (15 Apr 2024) 41.32%
Shares short (prior month 15 Mar 2024) 46.21k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-28.22%
Return on equity (ttm)-50.63%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -7.46M
Net income avi to common (ttm)-6.91M
Diluted EPS (ttm)-2.5000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.64M
Total cash per share (mrq)2.1
Total debt (mrq)41k
Total debt/equity (mrq)0.29%
Current ratio (mrq)4.81
Book value per share (mrq)2.75

Cash flow statement

Operating cash flow (ttm)-6.14M
Levered free cash flow (ttm)-3.63M